Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
40

Summary

Conditions
  • Coronavirus Infection
  • COVID
  • SARS COV2
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: randomized, controlled, multi-armed, open-label, interventional studyMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Empty capsule will sub-cutaneous injection of ivermectin will be usedPrimary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 60 years
Gender
Both males and females

Description

This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in mild to moderate symptomat...

This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in mild to moderate symptomatic patients who consent to randomization following a new diagnosis in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test remained positive..

Tracking Information

NCT #
NCT04472585
Collaborators
Not Provided
Investigators
Study Chair: Muhammad Ashraf, PhD University of Veterinary & Animal Sciences, Lahore, Pakistan Study Director: Shoaib Ashraf, PhD Harvard University Boston, USA Principal Investigator: Sohaib Ashraf, MBBS Shaikh Zayed Medical Complex, Pakistan Principal Investigator: Moneeb Ashraf, MBBS Mayo Hospital, Pakistan